Clinical Trial

An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Phase II open-label, parallel group, 2 sites (Brazil), designed to evaluate the long term safety and efficacy of study drug for the treatment of the MPS II.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2018-10-16; most recent amendment 2025-07-21.
Status change: Enrolling by Invitation → Active, Not Recruiting 2021-01-31
Status change: Not Yet Recruiting → Enrolling by Invitation 2019-07-03
Trial Details
NCT Number NCT03708965
Lead Sponsor JCR Pharmaceuticals Co., Ltd.
Conditions Mucopolysaccharidosis II
Enrollment 19 participants
Start Date 2019-01-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-24